Jens Schroeder Kemp Named Chief Marketing Officer at Axogen

Axogen Inc. has appointed Jens Schroeder Kemp as chief marketing officer. He will report directly to Board Chair, CEO, and President Karen Zaderej, and will oversee the development and execution of the company’s marketing strategies.

“I am thrilled to welcome Jens to Axogen. His extensive strategic marketing experience and track record of growth is an ideal addition to our team,” Zaderej said. “We look forward to leveraging his experience combined with the magnitude and strength of our clinical portfolio to drive increased surgeon adoption and support continued innovation of our nerve repair solutions.”

Kemp brings more than 20 years of strategic marketing, sales, and business development experience in high-growing medical technology to this newly-created role. He most recently worked as vice president of Marketing for Ambu Inc., where he led Ambu’s marketing efforts to create the single use endoscopy market across multiple clinical applications. Following Ambu’s acquisition of King Systems in 2012, Kemp developed and scaled the U.S. marketing function with new capabilities in health economics and market access, market development, and digital marketing. Across more than 15 years at Ambu, he held multiple roles in business development and marketing, and served as a member of the global management team. Prior to Ambu, Kemp was a management consultant at PERA (Production and Engineering Research Association), where his role included sales, marketing, and innovation strategies for medical device and renewable energy products. Previously, he was co-founder of an artificial intelligence decision support software company Mindgroup ApS.
 
“I am very pleased to be joining Axogen,” Kemp said. “Axogen’s portfolio offers clinical benefits to patients and healthcare providers, and I look forward to engaging with surgeons as we continue to innovate and change the standard of care for patients with nerve injuries.”
 
Kemp earned a bachelor’s degree in business administration, and a master’s degree in international marketing and management, both from Copenhagen Business School.
 
Axogen develops and commercializes peripheral nerve regeneration and repair technologies. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen’s platform for peripheral nerve repair features a portfolio of products, including Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; and Axoguard Nerve Cap, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.